Cargando…

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine

In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended for teenagers with out-o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watle, Sara Viksmoen, Næss, Lisbeth Meyer, Tunheim, Gro, Caugant, Dominique A., Wisløff, Torbjørn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475610/ https://www.ncbi.nlm.nih.gov/pubmed/33631080 http://dx.doi.org/10.1080/21645515.2021.1880209

Ejemplares similares

Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors
por: Watle, S. V., et al.
Publicado: (2020)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016
por: Campbell, Helen, et al.
Publicado: (2017)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults
por: Tipton, Mary, et al.
Publicado: (2018)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

2461. Safety of Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid-Conjugate Vaccine in Adolescents
por: Myers, Tanya, et al.
Publicado: (2018)

Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations
por: Cheng, Wendy Y., et al.
Publicado: (2019)

Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
por: Kensinger, Richard, et al.
Publicado: (2022)

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis
por: Conti, Andrea, et al.
Publicado: (2023)

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines
por: Findlow, Jamie, et al.
Publicado: (2019)

Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study
por: Ohm, Milou, et al.
Publicado: (2023)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

1080 Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination
por: Block, Stanley L., et al.
Publicado: (2014)

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine
por: O’Connor, Daniel, et al.
Publicado: (2017)

2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?
por: Cheng, Wendy, et al.
Publicado: (2018)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
por: Zambrano, Betzana, et al.
Publicado: (2023)

2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
por: Simon, Michael W, et al.
Publicado: (2019)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel
por: Patel, Manisha, et al.
Publicado: (2014)

Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults
por: Kim, Han Wool, et al.
Publicado: (2019)

NMR Assays for Estimating the O-Acetyl Content of Meningococcal Polysaccharide Serogroup A in Quadrivalent Conjugate Vaccine Formulation
por: Martini, Silvia, et al.
Publicado: (2019)

Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada
por: Delea, Thomas E., et al.
Publicado: (2017)

Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
por: Gamougam, Kadidja, et al.
Publicado: (2015)

Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine
por: Elias, Johannes, et al.
Publicado: (2013)

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
por: Presa, Jessica, et al.
Publicado: (2019)

Safety and immunogenicity of two doses of quadrivalent meningococcal conjugate vaccine or one dose of meningococcal group C conjugate vaccine, both administered concomitantly with routine immunization to 12- to 18-month-old children
por: Noya, Francisco, et al.
Publicado: (2014)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ra677j6bsh8sd7680hvd2gjv0r